title: The Hollow Fiber System Model in the Nonclinical Evaluation of Antituberculosis Drug Regimens.
authors.affiliation: Center for Drug Evaluation and Research, Office of Clinical Pharmacology, Office of Translational Sciences.
authors.forename: Dakshina
authors.initials: D
authors.lastname: Chilukuri
authors.affiliation: Office of New Drugs, US Food and Drug Administration, Silver Spring, Maryland.
authors.forename: Owen
authors.initials: O
authors.lastname: McMaster
authors.affiliation: Center for Drug Evaluation and Research, Office of Clinical Pharmacology, Office of Translational Sciences.
authors.forename: Kimberly
authors.initials: K
authors.lastname: Bergman
authors.affiliation: Center for Drug Evaluation and Research, Office of Clinical Pharmacology, Office of Translational Sciences.
authors.forename: Philip
authors.initials: P
authors.lastname: Colangelo
authors.affiliation: Office of New Drugs, US Food and Drug Administration, Silver Spring, Maryland.
authors.forename: Kerry
authors.initials: K
authors.lastname: Snow
authors.affiliation: Office of New Drugs, US Food and Drug Administration, Silver Spring, Maryland.
authors.forename: Joseph G
authors.initials: JG
authors.lastname: Toerner
mesh_terms: D000995:Antitubercular Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D008954:Models, Biological; D009169:Mycobacterium tuberculosis / Q000187:drug effects*; D014376:Tuberculosis / Q000188:drug therapy*
chemical_list: D000995:Antitubercular Agents
keywords: antimycobacterial; in vitro; tuberculosis